Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: A randomized and controlled double blind study

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 7, 2009, Pages 762-770

  Malaguarnera, Mariano ^a,b   Risino, Corrado ^a   Cammalleri, Lisa ^a   Malaguarnera, Lucia ^a   Astuto, Marinella ^a   Vecchio, Ignazio ^a   Rampello, Liborio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Departments of Senescence Urological and Neurological Sciences   (Italy)

Author keywords

Ammonia; Branched chain amino acids; Cirrhosis; Hepatic coma; L acetylcarnitine

Indexed keywords

AMMONIA; BRANCHED CHAIN AMINO ACID; LEVACECARNINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FEMALE; GLASGOW COMA SCALE; HEPATIC COMA; HUMAN; LIVER CIRRHOSIS; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UREA NITROGEN BLOOD LEVEL;

ACETYLCARNITINE; AMINO ACIDS, BRANCHED-CHAIN; AMMONIA; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; VITAMIN B COMPLEX;

EID: 67651053228     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328309c791     Document Type: Article

References (67)

1. Ferenci P, Lockwood A, Mullen K, Tarter R,Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final Report Of The Working Party At The 11th World Congresses Of Gastroenterology, Vienna, 1998. J Hepatol 2002; 35:716-721. (Pubitemid 34183979)
2. Hazell AS, Butterworth RF. Hepatic encephalopathy: an update of pathophysiologic mechanisms. Proc Soc Exp Biol Med 1999; 222:99-112. (Pubitemid 29514124)
3. Malaguarnera M, Pistone G, Trovato BA, Scuderi M, Vinci M, Romano M, Marletta F. Electrophysiological alterations in hepatic encephalopathy detected by brain mapping. Panminerva Med 1996; 38:84-88. (Pubitemid 126457580)
4. Mechtcheriakov S, Graziadei IW, Kugener A, Wiedemann J, Galbavy C, Hinterhuber H, et al. Multidimensional assessment of neuro-psychiatric symptoms in patients with low-grade hepatic encephalopathy: a Clinical Rating Scale. World J Gastroenterol 2005; 11:5893-5898. (Pubitemid 41662846)
5. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002; 67:259-279.
6. Perea G, Araque A. Communication between astrocytes and neurons: a complex language. J Physiol Paris 2002; 96:199-207. (Pubitemid 36090356)
7. Hasel KM, Summers BA, De Lahunta A. Encephalopathy with idiopathic hyperammonaemia and Alzheimer type II astrocytes in equidae. Equine Vet J 1999; 31:478-482. (Pubitemid 129650655)
8. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003; 18:61-71. (Pubitemid 36343974)
9. Malaguarnera M, Pistone G, Astuto M, Dell'Arte S, Finocchiaro G, Lo Giudice E, Pennisi G. L-carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003; 21:271-275. (Pubitemid 37323484)
10. Malaguarnera M, Pistone G, Rampello E, Leotta C, Scarpello L, Rampello L. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005; 11:7197-7202. (Pubitemid 43154020)
11. Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branchedchain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985; 5:282-289. (Pubitemid 16203415)
12. Berlin JA, Chalmers TC. Meta-analysis of branched-chain amino acids in hepatic encephalopathy. Gastroenterology 1989; 97:1043-1045. (Pubitemid 19239050)
13. Howard J. Branched chain amino acid in hepatic encephalopathy. Am J Surg 2002; 183:424-429. (Pubitemid 34442508)
14. Morgan MY, Blei A, Grungreiff K, Jalan R, Kircheis G, Marchesini G, et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007; 22:389-405.
15. Yamamoto M, Iwasa M, Matsumura K, Nakagawa Y, Fujita N, Kobayashi Y, et al. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol 2005; 11:6792-6799. (Pubitemid 43092450)
16. Fischer JE, Funovics JM, Aguirre A, James JH, Keane JM,Wesdorp RI, et al. The role of plasma amino acids in hepatic encephalopathy. Surgery 1975; 78:276-290.
17. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976; 80:77-91.
18. Fischer JE, Yoshimura N, Aguirre A, James JH, Cummings MG, Abel RM, Deindoerfer F. Plasma amino acids in patients with hepatic encephalopathy. Effects of amino acid infusions. Am J Surg 1974; 127:40-47.
19. Desjardins P, Rao KV, Michalak A, Rose C, Butterworth RF. Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle. Metab Brain Dis 1999; 14:273-280. (Pubitemid 30337701)
20. Eriksson LS, Persson A, Wahren J. Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 1982; 23:801-806. (Pubitemid 12018505)
21. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11:92-101. (Pubitemid 20250834)
22. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al.; Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124:1792-1801.
23. Plauth M, Egberts EH, HamsterW, Torok M, Muller PH, Brand O, et al. Longterm treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. J Hepatol 1993; 17:308-314. (Pubitemid 23134926)
24. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. Br Med J 2004; 328:1046. (Pubitemid 38580827)
25. Farrel L, Vogel J, Bierber LL. Entry of L-acetylcarnitine into biosynthetic pathways. Biochim Biophys Acta 1986; 876:175-177.
26. Tao RC, Peck GK, Yoshimura NN. Effect of carnitine on liver fat and nitrogen balance in intravenously fed growing rats. J Nutr 1981; 111:171-177.
27. Bohles H, Segerer H, Fekl W, Stehr K. Animal experiment studies on the changes in lipid and protein metabolism in L-carnitine-supplemented total parenteral nutrition. Infusionsther Klin Ernahr 1983; 10:24-31. (Pubitemid 13154382)
28. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 2003; 53:S39-S47.
29. Schoemaker JH. Pharmacological treatment of diabetic peripheral neuropathy: challenges and possibilities. Br J Clin Pract 1994; 48:91-96. (Pubitemid 24099699)
30. Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 1995; 38:123.
31. Malaguarnera M, Di Mauro A, Gargante PM, Rampello L. L-carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. South Med J 2006; 99:315-316.
32. Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, et al. Double-blind parallel design pilot study of acetyl-L-carnitine in patients with Alzheimer's disease. Arch Neurol 1992; 49:1137-1141.
33. Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, et al. Long term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41:1726-1732.
34. Jones EA, Gammal SA. Hepatic encephalopathy. In: Arias IM, Jakoby WB, Popper H, et al., editors. The Liver: Biology and Photobiology. 2nd Edition. New York: Raven Press; 1988.
35. Liver Dis 1983; 3:298-307.
36. Conn HO. Pathogenesis of portal-systemic encephalopathy. In: Conn HO, Lieberthal MM, editors. The hepatic coma syndromes and lactulose. Baltimore: Williams And Wilkims; 1979:46-84.
37. Pappas SC, Jones EA. Methods for assessing hepatic encephalopathy. Semin Liver Dis 1983; 3:298-307.
38. Barry A. Mizock "nutritional support in hepatic encephalopathy" . Nutrition 1999; 3:220-228.
39. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19:424-430. (Pubitemid 24029921)
40. Blei AT. Treatment of hepatic encephalopathy. Lancet 2005; 365:1383-1384.
41. Tesdale G, Jennet B. Assessment of coma and impaired consciousness. Lancet 1974; 2:81-83.
42. Teasdale GM, Murray L. Revisiting the Glasgow Coma Scale and Coma Score. Intensive Care Med 2000; 26:153-154. (Pubitemid 30186586)
43. Van Der Rijt C, Schalm SW. Quantitative EEG analysis and survival in liver disease. Electroencephalogr Clin Neurophysiol 1985; 61:502-504. (Pubitemid 16212563)
44. De Fonseca-Wollheim F. Direkte plasmaammoniakbestimmung ohne enteiweissung. Clin Chem Clin Biochem 1973; 11:421-431.
45. Selberg O, Burchert W, Vd Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism. J Clin Invest 1993; 91:1897-1902. (Pubitemid 23141457)
46. Schafer DF, Jones EA. Potential neural mechanisms in the pathogenesis of hepatic encephalopathy. Prog Liver Dis 1982; 7:615-627.
47. Yurdaydin C, Hortnagl H, Steindl P, Zimmermann C, Pifl C, Singer EA, et al. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. J Hepatol 1990; 12:695-700. (Pubitemid 20349253)
48. Moroni F, Carpenedo R, Venturini I, Baraldi M, Zeneroli ML. Oxindole in pathogenesis of hepatic encephalopathy. Lancet 1998; 351:1861.
49. Haussinger D, Kircheis G, Fischer R, Schliess F, Vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035-1038.
50. Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974; 83:16-28.
51. James JH, Escourrou J, Fischer JE. Blood-brain neutral amino acid transport activity is increased after portacaval anastomosis. Science 1978; 200:1395-1397. (Pubitemid 8373560)
52. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproateinduced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114:1-7.
53. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002; 17:367-373.
54. Brusilow SW. Hyperammonemic encephalopathy. Medicine (Baltimore) 2002; 81:240-249.
55. Llansola M, Erceg S, Hernandez-Viadel M, Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis 2002; 17:389-397. (Pubitemid 36204768)
56. Marcaida G, Felipo V, Hermenegildo C, Minana MD, Grisolia S. Acute ammonia toxicity is mediated by the NMDA type of glutamate receptors. FEBS Lett 1992; 296:67-68.
57. Felipo V, Minana MD, Cabedo H, Grisolia S. L-carnitine increases the affinity of glutamate for quisqualate receptors and prevents glutamate neurotoxicity. Neurochem Res 1994; 19:373-377. (Pubitemid 24054810)
58. Eaton S, Bartlett K, Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem J 1996; 320:345-357.
59. Bartlett K, Eaton S. Mitochondrial beta-oxidation. Eur J Biochem 2004; 271:462-469.
60. Bieber LL. Carnitine. Annu Rev Biochem 1988; 57:261-283.
61. Roe CR, Millington DS, Maltby DA, Kahler SG, Bohan TP. L-carnitine therapy in isovaleric acidemia. J Clin Invest 1984; 74:2290-2295.
62. Muller DM, Seim H, Kiess W, Loster H, Richter T. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Metabolism 2002; 51:1389-1391.
63. Fritz IB. Carnitine and its role in fatty acid metabolism. ADV Lipid Res 1963; 64:285-334.
64. Singh RB, Naiz MA. Evaluation of oxidative stress in diabetics. J Assoc Physicians India 1995; 43:654.
65. Matsuoka M, Igisu H, Kohriyama K, Inoue N. Suppression of neurotoxicity of ammonia by L-carnitine. Brain Res 1991; 567:328-331.
66. Mccandless DW, Schenker S. Effect of acute ammonia intoxication on energy stores in the cerebral reticular activating system. 1981; 44:325-330.
67. Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 2006; 51:2242-2247.